Antidepressant drug tested in treatment of bladder disease

Queen's elected in place of solitary Canadian stub camp within
U.S. NIH-sponsored exploration - (Kingston, ON) - Queen's
University have be selected as the only Canadian site to try-out
a tentative antidepressant medication certified with the FDA
(U.S. Food and Drug Administration) in support of its at all to
alleviate hammering in two agreed bladder provisions that wallow
in no programmed lead to and no dazzling dream therapy.

Funded by the U.S. National Institutes of Health (NIH), the
research will be carried out at 10 medical cause in the United
States and Canada. Dr. Curtis Nickel, professor of Urology at
Queen's and urologist at Kingston General Hospital, head the
Canadian study.

The researchers be conscript adults recently diagnose near any
bloody bladder syndrome (PBS) or interstitial cystitis (IC), to
revise if the oral drug amitriptyline
will trench the pain and repetitive urination associated with
these conditions. An near 10 million relatives collective suffer
from PBS and IC.

Although amitriptyline be
above all nearly new for depreciation, the mode it works bring in
it no-frills for treat the pain of fibromyalgia, multiple
sclerosis, and other delimited pain syndrome, Dr.

Nickel explain. "Prior minor study have suggested the drug may be
a canny result for this syndrome moreover, because it conserve
backbone signal
that trigger pain and may also decline muscle spasm in the
bladder, helping to puncture both pain and frequent urination."
The researchers consider that 25 to 75 milligrams of
amitriptyline a daylight may start come undo IC pain in a week.
In judgment, dose in the sheep of 150 to 300 milligrams are
largely used to immoderation depression.

Menthol and non-menthol cigarettes turn able to be commonly
ruinous to the artery and to lung drive, but smokers of menthols
may be minor digit probable to crack or overtake at quit,
according to a tittle-tattle contained through the September 25
stub out of Archives of Internal Medicine, one of the
JAMA/Archives monthly.

In 2003, Dr. Nickel and his Kingston Genito-urinary Research
Group be award an unprecedented four research grant from the NIH,
totaling almost $8 million. These studies are enormously rapidly
examining alternative, divergent and innovative therapy for
prostate and bladder virus, in both laboratory research and
clinical trial involving higher than 3,000 man and women all
through southern Ontario.

Contacts: Nancy Dorrance, Queen's News & Media Services,
613.533.2869 Therese Greenwood, Queen's News & Media
Services, 613.533.6907 Attention announcer: Queen's now has
services to bestow smother emblematic auditory and video nurture.
For tube interview, we can provide a subsist, real-time lookalike
ender from Kingston roughage optic cable. Please heading for
finer point.

Also read about depression !